And sometimes you can find stocks that are especially great bargains. Three Motley Fool contributors believe they've done just that. Here's ...

Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer has beaten Wall Street's revenue estimate ... including through the acquisition of Seagen and Biohaven Pharmaceuticals, which allowed it to rejuvenate its cancer and neuroscience franchises.

For Pfizer Inc., the strategy has been “go big ... the deals included the $11.6 billion acquisition of migraine drug maker Biohaven Pharmaceutical Holding Co. Ltd and the $5.4 billion ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Biohaven acquired BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, as part of a February 2022 buyout of Channel Biosciences, a subsidiary of Knopp Biosciences. In October 2022, ...